|
|
髓系免疫细胞在肝细胞癌中标记基因的鉴定及免疫特征
|
Abstract:
目的：肝细胞癌(HCC)是全球第四大癌症相关死亡原因，且治疗选择有限。髓源免疫抑制细胞(MDSC)是在肿瘤微环境中(TME)中表现为免疫抑制活性的细胞群。在肝细胞癌中少有对MDSC特征标记的研究，同时缺少评价MDSC与免疫治疗关系的研究。方法：我们以肝细胞癌的单细胞数据为基础，鉴定了肝细胞癌的标记基因。进一步联合TCGA的数据开发了MDSC评分工具并探究与免疫治疗的关系。结果：我们鉴定了肝细胞癌中MDSC的11个特征基因，并基于此开发了一种ssGSEA工具评价MDSC的浸润。我们发现MDSC浸润影响患者预后并对免疫治疗具有抵抗作用。结论：肝细胞癌中MDSC的浸润对预后和免疫治疗具有不良影响。
Objective: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide and has limited treatment options. Myeloid-derived immunosuppressive cells (MDSC) are a population of cells that exhibit immunosuppressive activity in the tumor microenvironment (TME). There are few studies of MDSC signature markers in hepatocellular carcinoma, as well as a lack of studies evaluating the relationship between MDSC and immunotherapy. Methods: We identified marker genes for MDSC based on single-cell data in hepatocellular carcinoma. We further developed an MDSC scoring tool using TCGA data and explored the relationship with immunotherapy. Results: We identified 11 genes that characterize MDSC in hepatocellular carcinoma and developed a ssGSEA tool based on them to evaluate MDSC infiltration. We found that MDSC infiltration affected patient prognosis and was resistant to immunotherapy. Conclusion: Infiltration of MDSC in hepatocellular carcinoma has an adverse effect on prognosis and immunotherapy.
| [1] | Wu, M., Yang, S., Feng, X., Li, C., Liu, X., Zhang, Z., et al. (2021) Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma after Partial Hepatectomy. Journal of Inflammation Research, 14, 3231-3245. https://doi.org/10.2147/jir.s316177 |
| [2] | Chen, L., Yang, Z., Cao, Y., Hu, Y., Bao, W., Wu, D., et al. (2021) Pan-Cancer Analysis and Single-Cell Analysis Revealed the Role of ABCC5 Transporter in Hepatocellular Carcinoma. Channels, 15, 541-554. https://doi.org/10.1080/19336950.2021.1968592 |
| [3] | Du, F., Yang, L., Liu, J., Wang, J., Fan, L., Duangmano, S., et al. (2023) The Role of Mitochondria in the Resistance of Melanoma to PD-1 Inhibitors. Journal of Translational Medicine, 21, Article No. 345. https://doi.org/10.1186/s12967-023-04200-9 |
| [4] | Tian, H., Cao, J., Li, B., Nice, E.C., Mao, H., Zhang, Y., et al. (2023) Managing the Immune Microenvironment of Osteosarcoma: The Outlook for Osteosarcoma Treatment. Bone Research, 11, Article No. 11. https://doi.org/10.1038/s41413-023-00246-z |
| [5] | Marin-Acevedo, J.A., Dholaria, B., Soyano, A.E., Knutson, K.L., Chumsri, S. and Lou, Y. (2018) Next Generation of Immune Checkpoint Therapy in Cancer: New Developments and Challenges. Journal of Hematology & Oncology, 11, Article No. 39. https://doi.org/10.1186/s13045-018-0582-8 |
| [6] | Tripathi, S., Najem, H., Mahajan, A.S., Zhang, P., Low, J.T., Stegh, A.H., et al. (2022) cGAS-STING Pathway Targeted Therapies and Their Applications in the Treatment of High-Grade Glioma. F1000Research, 11, Article 1010. https://doi.org/10.12688/f1000research.125163.1 |
| [7] | Mandruzzato, S., Brandau, S., Britten, C.M., Bronte, V., Damuzzo, V., Gouttefangeas, C., et al. (2016) Toward Harmonized Phenotyping of Human Myeloid-Derived Suppressor Cells by Flow Cytometry: Results from an Interim Study. Cancer Immunology, Immunotherapy, 65, 161-169. https://doi.org/10.1007/s00262-015-1782-5 |
| [8] | Alshetaiwi, H., Pervolarakis, N., McIntyre, L.L., Ma, D., Nguyen, Q., Rath, J.A., et al. (2020) Defining the Emergence of Myeloid-Derived Suppressor Cells in Breast Cancer Using Single-Cell Transcriptomics. Science Immunology, 5, eaay6017. https://doi.org/10.1126/sciimmunol.aay6017 |
| [9] | Zhu, G., Tang, Z., Huang, R., Qu, W., Fang, Y., Yang, R., et al. (2023) CD36+ Cancer-Associated Fibroblasts Provide Immunosuppressive Microenvironment for Hepatocellular Carcinoma via Secretion of Macrophage Migration Inhibitory Factor. Cell Discovery, 9, Article No. 25. https://doi.org/10.1038/s41421-023-00529-z |
| [10] | Bronte, V., Brandau, S., Chen, S., Colombo, M.P., Frey, A.B., Greten, T.F., et al. (2016) Recommendations for Myeloid-Derived Suppressor Cell Nomenclature and Characterization Standards. Nature Communications, 7, Article No. 12150. https://doi.org/10.1038/ncomms12150 |
| [11] | Millrud, C.R., Bergenfelz, C. and Leandersson, K. (2016) On the Origin of Myeloid-Derived Suppressor Cells. Oncotarget, 8, 3649-3665. https://doi.org/10.18632/oncotarget.12278 |
| [12] | Gabrilovich, D.I. (2017) Myeloid-Derived Suppressor Cells. Cancer Immunology Research, 5, 3-8. https://doi.org/10.1158/2326-6066.cir-16-0297 |
| [13] | Daly, R.J., Scott, A.M., Klein, O. and Ernst, M. (2022) Enhancing Therapeutic Anti-Cancer Responses by Combining Immune Checkpoint and Tyrosine Kinase Inhibition. Molecular Cancer, 21, 189. https://doi.org/10.1186/s12943-022-01656-z |
| [14] | Qiu, J., Wang, H., Lv, X., Mao, L., Huang, J., Hao, T., et al. (2023) Hepatocellular Carcinoma Cell Differentiation Trajectory Predicts Immunotherapy, Potential Therapeutic Drugs, and Prognosis of Patients. Open Life Sciences, 18, Article 20220656. https://doi.org/10.1515/biol-2022-0656 |
| [15] | Oshiro, Y., Mizumoto, M., Hisanaga, T., Tanaka, K., Komine, M., Takahashi, M., et al. (2023) Abscopal Effect with Fever of Unknown Cause during Radiotherapy: Two Case Reports and Review of the Literature. Experimental and Therapeutic Medicine, 26, Article No. 510. https://doi.org/10.3892/etm.2023.12209 |
| [16] | Kusmartsev, S., Su, Z., Heiser, A., Dannull, J., Eruslanov, E., Kübler, H., et al. (2008) Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 14, 8270-8278. https://doi.org/10.1158/1078-0432.ccr-08-0165 |
| [17] | Mok, S., Koya, R.C., Tsui, C., Xu, J., Robert, L., Wu, L., et al. (2014) Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Research, 74, 153-161. https://doi.org/10.1158/0008-5472.can-13-1816 |
